Design Retrospective cohort study, with passive follow-up and conditional survival analysis to account for unidentified loss to follow-up. Setting and participants 15 174 Olympic athletes from nine ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy ...

Patients with mild to moderate sleep apnea had lower mortality rates than those with no sleep apnea and those with severe sleep apnea.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...